KalVista Pharmaceuticals (KALV) Consolidated Net Income (2014 - 2025)

KalVista Pharmaceuticals has disclosed Consolidated Net Income across 12 years of filings, most recently posting -$60.1 million for Q3 2025.

• Consolidated Net Income for Q3 2025 came in at -$60.1 million, down 48.7% year-over-year; the trailing twelve-month figure through Jul 2025 was -$65.2 million (up 5.68% YoY), and the FY2025 annual result was -$91.8 million, down 74.34% from the prior year.
• Consolidated Net Income came in at -$60.1 million for Q3 2025 at KalVista Pharmaceuticals, down from $39.4 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $39.4 million in Q2 2025 to a low of -$60.1 million in Q3 2025.
• The 5-year median for Consolidated Net Income is -$26.3 million (2022), against an average of -$22.0 million.
• Across the five-year window, Consolidated Net Income slumped 111.06% in 2022 and soared 194.87% in 2024, its largest moves.
• KalVista Pharmaceuticals' Consolidated Net Income stood at -$23.3 million in 2021, then retreated by 9.1% to -$25.4 million in 2022, then fell by 13.9% to -$29.0 million in 2023, then tumbled by 53.45% to -$44.5 million in 2024, then sank by 35.28% to -$60.1 million in 2025.
• The last three Consolidated Net Income figures came in at -$60.1 million (Q3 2025), $39.4 million (Q2 2025), and -$44.5 million (Q4 2024), per Business Quant data.